Marina Sol
Founder/CEO
Website unreachable since Oct 27, 2026
Diagnio offers at-home hormonal testing using saliva samples to provide women with lab-accurate insights into their reproductive health, including fertility and menopause. The platform enables users to monitor their hormonal levels privately and conveniently, facilitating informed health decisions without the need for in-person lab visits.
Raised to date
$50KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founder/CEO
Women often face challenges in accessing convenient and private methods for monitoring their hormonal health, especially concerning fertility, pregnancy planning, postpartum recovery, and menopause. Traditional lab visits can be time-consuming, costly, and may not provide the continuous monitoring needed for informed decision-making.
Diagnio provides at-home hormonal testing solutions, leveraging saliva-based diagnostics and blood test panels to deliver lab-accurate insights into women's reproductive health. The platform enables users to monitor their hormone levels from the comfort of their homes, offering a convenient and private alternative to traditional lab visits. Diagnio combines these testing solutions with an AI-powered health assistant, GynoAssist, accessible via a mobile app, providing personalized advice, symptom tracking, and risk assessments. By integrating at-home diagnostics with AI-driven support, Diagnio empowers women to proactively manage their hormonal health and make informed decisions at every stage of life.
Diagnio primarily targets women seeking accessible, private, and convenient ways to monitor their hormonal health throughout various life stages, including fertility, pregnancy, postpartum recovery, and menopause.